

## PAC 2014 - Global Partnering for Open Innovation Program

2014. 11. 18 ~ 11.19, Ritz-Carlton SEOUL, Grand Ballroom A3F

Day 1: Nov 18 (Tuesday)		HOST: Jung-Ryun Ahn (GSK)
8:30 (30')	<b>Registration</b>	
9:00 (10')	<b>Opening remarks:</b> <ul style="list-style-type: none"> <li>• <b>Kyung-Ho Lee</b>, KPMA/Chairman</li> <li>• <b>Jin-Ho Kim</b>, KRPIA/Chairman</li> </ul>	
9:10 (10')	<b>Welcome Address:</b> <ul style="list-style-type: none"> <li>• Minister or Vice Minister of MOHW (TBD)</li> <li>• <b>Chunjin Kim</b>, Chair of National Assembly Health &amp; Welfare Committee</li> </ul>	
9:20 (50')	<b>Keynote Speech:</b> Chair: <b>Woolck Jang</b> , Handok Inc. <ul style="list-style-type: none"> <li>• <b>ByoungJun Bae</b>, MOHW/ Director General, Bureau of Health Industry (TBD)  <b>Government Policy for Pharma Industry: Vision &amp; Goal of 5-year Comprehensive Plan</b></li> <li>• <b>Robert J. Hariri</b>, Celgene/Chairman, Founder and CSO for Cellular Therapeutics  <b>New Paradigm of Pharma R&amp;D for Efficiency and Success</b></li> </ul>	
10:10 (60')	<b>Session R-1: R&amp;D Innovation Through Partnership in Asia</b> Chair: <b>Yil-Seob Lee</b> , GSK <ul style="list-style-type: none"> <li>• <b>Duncan McKay</b>, GSK/VP, EMAP R&amp;D;  <b>GSK External R&amp;D Innovation in Emerging Market and AsiaPacific</b></li> <li>• <b>Jia-hua Wang</b>, Novartis Oncology/Director, Asia Pacific Region Medical Affairs  <b>Baek Min Seong</b>, Novartis/ Head, Strategic partnership Korea/Asia Lead in BD&amp;L  <b>R&amp;D Opportunity &amp; Partnership in Asia</b> <ul style="list-style-type: none"> <li>• Q&amp;A</li> </ul> </li> </ul>	
11:10 (20')	<b>Coffee Break</b>	
11:30 (60')	<b>Session M-1: Novel Drug Discovery for Orphan Diseases</b> Chair: <b>Joong-Gon, Kim</b> , Seoul National University <ul style="list-style-type: none"> <li>• <b>Jei-Wook Chae</b>, Bioneer Inc./  <b>Idiopathic Pulmonary Fibrosis</b></li> <li>• <b>YoungKyu Cho</b>, Handok Inc /  <b>IL-1RA hyFC Development for Rare Diseases</b></li> <li>• <b>Wan Namkung</b>, Yonsei University  <b>Identification of Small-Molecule Correctors for ΔF508-CFTR Using High-throughput Screening</b></li> <li>• Q&amp;A</li> </ul>	
12:30 (60')	<b>Lunch Break</b>	

13:30 (60')	<b>Session R-2: R&amp;D Collaboration for Innovation</b> Chair: <b>Su Nam</b> , Yuhan <ul style="list-style-type: none"> <li>• <b>Kenichi Nishida</b>, Daiichi-Sankyo/Senior Director, External Science Planning, R&amp;D planning <b>Early Phase Research Collaboration Activities Featuring TaNeDS Drug Discovery Program in Daiichi Sankyo</b></li> <li>• <b>Frank Degner</b>, Boehringer Ingelheim/ Head, Clinical Development &amp; Medical Affairs <b>Implications of Globalized Clinical Drug Development for Local and Regional Clinical Operations</b></li> <li>• Q&amp;A</li> </ul>
14:30 (60')	<b>Session M-2: Essence of KDDF(Korea Drug Development Fund) Projects</b> Chair: <b>Dong-Ho Lee</b> , Ulsan University <ul style="list-style-type: none"> <li>• <b>Kyeong- Cheon Jung</b>, Dinona Inc./ <b>JL1 epitope of CD43, a Novel Therapeutic Target in Acute Leukemia</b></li> <li>• <b>Sanghee, Yoo</b>, Hanall Biopharma./ <b>HL161: a Novel Anti-FcRn Antibody as a New Therapeutic Option For Autoimmune Diseases</b></li> <li>• <b>Yoon-Won Kim</b>, ImmuneMed Inc./ <b>Development of Newly Defined Antiviral Drug That Selectively Acts On the Viral Infected Cells</b></li> <li>• Q&amp;A</li> </ul>
15:30 (20')	<b>Coffee Break</b>
15:50 (70')	<b>Session R-3: Open Innovation Strategy for Biopharmaceuticals</b> Chair: <b>James Jun</b> , KT&G <ul style="list-style-type: none"> <li>• <b>Yariv Hefez</b>, Merck Serono/Vice president, Business Development, Licensing &amp; Alliance Management, Biosimilar division <b>The Role of Asia In a Global Biosimilar Business Strategy and Partnership Opportunities In Asia</b></li> <li>• <b>Yuan-Hua Ding</b>, Pfizer/ Executive Director, Head, External R&amp;D Innovation - AP <b>Alliances to Drive Biomedical Innovation (Subtitle: Overview of Pfizer R&amp;D, Partner Strategy and Asia Initiatives)</b></li> <li>• <b>Elena Rizova</b>, Janssen/ VP, J&amp;J Innovation center at Shanghai <b>Johnson &amp; Johnson as Catalyzer of innovation</b></li> <li>• Q&amp;A</li> </ul>
17:00 (60')	<b>Session M-3: Empowered biologics</b> Chair: <b>Young-Woo Park</b> , KRIBB <ul style="list-style-type: none"> <li>• <b>Jin-San Yoo</b>, PharmAbcine, Inc./CEO and President <b>Clinical Development of Tanibirumab and Its Next Generation of Bispecific Antibody</b></li> <li>• <b>Soon-Jae Park</b>, Alteogen Inc./CEO <b>Herceptin ADC by New ConjugationTechnology or Long Acting FVIIa by Use of NexP Fusion Technology</b></li> <li>• <b>Yong-Joo Kim</b>, LegoChem Biosciences Inc /CEO <b>Toward Well-defined ADC</b></li> <li>• Q&amp;A</li> </ul>
18:00	<b>Welcome Reception ( Invitation Only)</b>

Day 2: Nov 19 (Wednesday)		HOST: Myungha Park (BI)
7:30 (60')	<b>Breakfast meeting with gov't policy makers ( Invitation Only)</b> Organized by KPMA &KRPIA	
8:30 (30')	<b>Registration</b>	
9:00 (30')	<b>Keynote Speech: (TBD)</b> Chair: <b>Seong-Choon Choe</b> , Boryung Pharmaceutical <ul style="list-style-type: none"> <li>• <b>Si Young Song</b>, Yonsei Univ. Health System “ (TBD)”</li> </ul>	
9:30 (40')	<b>Session M-4 : Essence of National Oncoventure(NOV) projects</b> Chair: <b>In-Chul, Kim</b> , National Oncoventure/ <ul style="list-style-type: none"> <li>• <b>Jung Yong, Kim</b> , NOV/ Introduction of TGF-beta R1 Inhibitor Program of Medpacto Inc.</li> <li>• <b>Young-Whan Park</b>, NOV/ Introduction of Vascular Disrupting Agent Program of Chong Kun Dang Pharm</li> <li>• Q&amp;A</li> </ul>	
10:10 (60')	<b>Session R- 4: R&amp;D Alliance for Innovation</b> Chair: <b>Joy H.J. Chung</b> , KHIDI/Executive Consultant <ul style="list-style-type: none"> <li>• <b>Takato Noumi</b>, Sanofi/Director, External Science &amp; Partnering Japan <b>Sanofi's Strategy for Open Innovation and Partnering</b></li> <li>• <b>Hiroya Muranishi</b>, Takeda/ Senior Director, Research Alliance, Pharmaceutical Research Division <b>Takeda's Alliance Aapproach for Therapeutic Research Innovation</b></li> <li>• Q&amp;A</li> </ul>	
11:10 (50')	<b>Session M-5: First-in-class NCEs</b> Chair: <b>Bong Yong Lee</b> , Daewoong Pharmaceutical Co. Ltd./ Head of Research <ul style="list-style-type: none"> <li>• <b>Dong Hoon Jin</b>, Ulsan University <b>E3 Ubiquitin Ligase-dependent Pathway As a Novel Therapeutic Strategy</b></li> <li>• <b>Yong H Roh</b>, Obetat Biopharma/President <b>OBT1026: Novel Peptide Therapy for Severe Obesity</b></li> <li>• <b>Wheeseong Lee</b>, KT&amp;G Life Sciences <b>NAD Modulator for Mitochondrial Disorders</b></li> <li>• Q&amp;A</li> </ul>	
12:00 (5')	<b>Closing</b> KPMA Sangsuk Lee, KRPIA/CEO	